Current status of novel weight loss interventions

Centers for Disease Control and Prevention. Overweight and obesity: adult obesity facts, https://www.cdc.gov/obesity/data/adult.html (2022, accessed 23 November 2023).

Food and Drug Administration (FDA). FDA approves new drug treatment for chronic weight management, first since 2014, https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. (2021, accessed 23 November 2023).

Food and Drug Administration (FDA). FDA Approves new medication for chronic weight management, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management (2023, accessed 10 December 2023).

Collins L Costello RA . Glucagon-like peptide-1 receptor agonists. Updated January 13, 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, https://www.ncbi.nlm.nih.gov/books/NBK551568/ (2023, accessed 23 November 2023).

Wadden TA Bailey TS Billings LK , et al.; STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 2021; 325(14):1403–1413.

Rubino D Abrahamsson N Davies M , et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021; 325(14): 1414–1425.

Ruder K . At obesityweek, more data and questions about semaglutide, tirzepatide, and retatrutide. JAMA 2024; 331(1): 9–11.

Jastreboff AM Aronne LJ Ahmad NN , et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for treatment of obesity. N Engl J Med 2022; 387(3): 205–216.

Alkhezi OS Alahmed AA Alfayez OM , et al. Comparative effectiveness of glucon-like peptide-1 receptor agonist for the management of obesity in adults with diabetes: a network meta-analysis of randomized clinical trials. Obes Rev 2003; 24(3): e13543.

Jastreboff AM Kaplan LM Frías JP , et al.; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med 2023; 389(6): 514–526.

Abu Dayyeh BK Rajan E Gostout CJ (2013) Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointestinal Endoscopy 78(3): 530–535.

Abu Dayyeh BK Bazerbachi F Vargas EJ , et al. (2022). Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet (London, England) 400(10350): 441–451.

Novikov AA Afaneh C Saumoy M , et al. Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic band for weight loss: how do they compare? J Gastrointest Surg 2018; 22: 267–273.

Sharaiha RZ Hajifathalian K Kumar R , et al. (2021). Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatolo 19(5): 1051–1057.e2.

Verhoeff K Mocanu V Zalasky A , et al. Evaluation of metabolic outcomes following SADI-S: a systematic review and meta-analysis. Obes Surg 2022; 32(4): 1049–1063.

Yashkov Y Bordan N Torres A , et al. SADI-S 250 vs Roux-en-Y Duodenal Switch (RY-DS): results of 5-Year observational study. Obes Surg 2021; 31(2): 570–579.

Pereira SS Guimarães M Almeida R , et al. Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles. Int J Obes (Lond) 2019; 43(12): 2518–2527.

Guimarães M Pereira SS Holst JJ , et al. Can metabolite and hormone profiles provide a rationale for choosing between bariatric procedures? Obes Surg 2021; 31(5): 2174–2179.

Wang T Shen Y Qiao Z , et al. Comparison of diabetes remission and micronutrient deficiency in a mildly obese diabetic rat model undergoing SADI-S versus RYGB. Obes Surg 2019; 29(4): 1174–1184.

Huang J Chen Y Wang X , et al. Change in adipokines and gastrointestinal hormones after bariatric surgery: a meta-analysis. Obes Surg 2023; 33(3): 789–806.

Li X Hu X Fu C , et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y Gastric bypass for obesity: a meta-analysis and systematic review. Obes Surg 2023; 33(2): 611–622.

Robert M Espalieu P Pelascini E , et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet 2019; 393(10178): 1299–1309. Erratum in: Lancet. 2019; 393(10178): 1298.

Cornejo J Evans LA Castillo-Larios R , et al. One anastomosis gastric bypass as a primary bariatric surgery: MBSAQIP database analysis of short-term safety and outcomes. Surg Endosc 2024; 38(1): 270–279.

Shah K Nergård BJ Fagerland MW , et al. Limb length in gastric bypass in super-obese patients-importance of length of total alimentary small bowel tract. Obes Surg 2019; 29(7): 2012–2021.

Miras AD Kamocka A Pérez-Pevida B , et al. The effect of standard versus longer intestinal bypass on GLP-1 regulation and glucose metabolism in patients with type 2 diabetes undergoing Roux-en-Y gastric bypass: the long-limb Study. Diabetes Care 2021; 44(5): 1082–1090.